Oral mosapride can provide additional anti-emetic efficacy following total joint arthroplasty under general anesthesia: a randomized, double-blinded clinical trial

Table 2 Incidence of PONV during the first postoperative 48 h

	Control (n = 80)	Dexa (n = 82)	Mosa + Dexa (n = 78)	p*	p1^†	p2^†	p3^†
Total	44 (55%)	21 (25.6%)	8 (10.3%)	< 0.001	< 0.001	< 0.001	0.014
Nausea	35 (43.8%)	16 (19.5%)	5 (6.4%)	< 0.001	0.001	< 0.001	0.014
Vomiting	9 (11.2%)	5 (6.1%)	3 (3.9%)	0.176	NA	NA	NA
Complete response	36 (45%)	61 (74.4%)	70 (89.7%)	< 0.001	< 0.001	< 0.001	0.012
Severe PONV	15 (18.8%)	6 (7.3%)	1 (1.3%)	0.001	0.030	< 0.001	0.062

Data presented as number of patients (percentage)
Dexa dexamethasone; Mosa mosapride; PONV postoperative nausea and vomiting
* Uncorrected p values (for the three-way comparison)
^† Bonferroni-corrected p values: p1, Control vs Dexa; p2, Control vs. Mosa+Dexa; p3, Dexa vs. Mosa-Dexa. The corrected significance threshold was 0.016

ISSN: 1471-2253